Cholesteryl Ester Transfer Protein Intimately Involved in Dyslipidemia-Related Susceptibility to Cognitive Deficits in Type 2 Diabetic Patients

被引:5
|
作者
Sun, Jie [1 ,2 ]
Cai, Rongrong [1 ]
Huang, Rong [1 ]
Wang, Pin [1 ]
Tian, Sai [1 ]
Sun, Haixia [1 ]
Xia, Wenqing [1 ]
Wang, Shaohua [1 ]
机构
[1] Southeast Univ, Affiliated ZhongDa Hosp, Dept Endocrinol, 87 DingJiaQiao Rd, Nanjing 210009, Jiangsu, Peoples R China
[2] Southeast Univ, Sch Med, Nanjing, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
Cholesteryl ester transfer protein; dyslipidemia; memory decline; mild cognitive impairment; type; 2; diabetes; DENSITY-LIPOPROTEIN-CHOLESTEROL; ALZHEIMERS-DISEASE; INSULIN-RESISTANCE; PLASMA; GENE; CETP; POLYMORPHISM; SERUM; RISK; IMPAIRMENT;
D O I
10.3233/JAD-160053
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: Cholesteryl ester transfer protein (CETP) is involved in diabetic dyslipidemia. Objective: We aim to test the hypothesis that CETP might be of importance in mediating dyslipidemia-related susceptibility to cognitive deficits in diabetic patients. Methods: We recruited 190 type 2 diabetic patients and divided them into two groups according to the Montreal Cognitive Assessment (MoCA) score. The association between CETP and cognitive decline was analyzed with logistic regression and stratification. Results: There were 110 diabetic patients with mild cognition impairment (MCI) and 80 healthy cognition subjects as controls. Dyslipidemia is more common among diabetic patients with MCI; they had a significant increase of serum CETP concentrations, which was negatively correlated with MoCA (r = -0.638; p < 0.001). Negative correlations were also found between the serum CETP concentration with the Auditory Verbal Learning Test (r = -0.266; p = 0.008), indicating memory deficit. Logistic regression analysis revealed that CETP concentration was an independent factor of diabetic MCI (p < 0.001). Further stratification study showed that high serum levels of CETP was an independent risk factor of MCI in diabetic patients with a lowdensity lipoproteins level >= 2.59 mmol/L, or high density lipoproteins level <= 1.0 mmol/L for men and <= 1.3 mmol/L for women, or TG level >= 1.7 mmol/L, after adjusting for age, sex, education, and glucose control (all ps < 0.05). Conclusions: CETP was intimately involved in dyslipidemia-related susceptibility to cognitive decline, especially memory function in type 2 diabetic patients.
引用
收藏
页码:175 / 184
页数:10
相关论文
共 50 条
  • [21] Association between cholesteryl ester transfer protein activity and coronary artery disease complication in Tunisian patients with type 2 diabetes
    Hammami, M
    Chaaba, R
    Hammami, S
    Attia, N
    Mahjoub, S
    Smaoui, M
    Ben Hamd, K
    Ben Farhat, M
    ATHEROSCLEROSIS SUPPLEMENTS, 2004, 5 (01) : 39 - 39
  • [22] Relationship between TaqIB cholesteryl ester transfer protein gene polymorphism and macrovascular complications in Japanese patients with type 2 diabetes
    Kawasaki, I
    Tahara, H
    Emoto, M
    Shoji, T
    Nishizawa, Y
    DIABETES, 2002, 51 (03) : 871 - 874
  • [23] Effects of the Cholesteryl Ester Transfer Protein Inhibitor, Evacetrapib, Administered as Monotherapy or in Combination With Statins on Cholesterol Efflux and HDL Particles in Patients With Dyslipidemia
    Rader, Daniel J.
    Ruotolo, Giacomo
    Kane, John P.
    Wang, Ming-Dauh
    Krueger, Kathryn A.
    Nissen, Steven E.
    Nicholls, Stephen J.
    Brewer, Bryan H.
    CIRCULATION, 2014, 130
  • [24] Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes
    van Venrooij, FV
    Stolk, RP
    Banga, JD
    Sijmonsma, TP
    van Tol, A
    Erkelens, DW
    Dallinga-Thie, GM
    DIABETES CARE, 2003, 26 (04) : 1216 - 1223
  • [25] Type 2 diabetes mellitus is associated with differential effects on plasma cholesteryl ester transfer protein and phospholipid transfer protein activities and concentrations
    Dullaart, RPF
    De Vries, R
    Scheek, L
    Borggreve, SE
    Van Gent, T
    Dallinga-Thie, GM
    Ito, M
    Nagano, M
    Sluiter, WJ
    Hattori, H
    Van Tol, A
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2004, 64 (03): : 205 - 215
  • [26] Decrease in plasma cholesteryl-ester transfer protein activity with simvastatin treatment in patients with type IIa hypercholesterolemia
    Hibino, T
    Sakuma, N
    Sato, T
    Yoneyama, A
    Fujinami, T
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1996, 57 (01): : 42 - 47
  • [27] The effect of glycemic control in type 2 diabetic patients with diabetes-related dyslipidemia
    Abdel-Gayoum, AGA
    SAUDI MEDICAL JOURNAL, 2004, 25 (02) : 207 - 211
  • [28] Pioglitazone Decreases Plasma Cholesteryl Ester Transfer Protein Mass, Associated With a Decrease in Hepatic Triglyceride Content, in Patients With Type 2 Diabetes
    Jonker, Jacqueline T.
    Wang, Yanan
    de Haan, Willeke
    Diamant, Michaela
    Rijzewijk, Luuk J.
    van der Meer, Rutger W.
    Lamb, Hildo J.
    Tamsma, Jouke T.
    de Roos, Albert
    Romijn, Johannes A.
    Rensen, Patrick C. N.
    Smit, Johannes W. A.
    DIABETES CARE, 2010, 33 (07) : 1625 - 1628
  • [29] Expression of Type IIA Secretory Phospholipase A 2 Inhibits Cholesteryl Ester Transfer Protein Activity in Transgenic Mice
    Hurt-Camejo, Eva
    Gautier, Thomas
    Rosengren, Birgitta
    Dikkers, Arne
    Behrendt, Margareta
    Grass, David S.
    Rader, Daniel J.
    Tietge, Uwe J. F.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2013, 33 (12) : 2707 - 2714
  • [30] Suppression of hepatic cholesteryl ester transfer protein expression in obese humans with the development of type 2 diabetes mellitus
    MacLean, PS
    Vadlamudi, S
    MacDonald, KG
    Pories, WJ
    Barakat, HA
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (04): : 2250 - 2258